# Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required)

Source: https://welltoldgrants.com/grants/rfa-ca-24-028-limited-competition-aids-malignancy-consortium-amc-um1/  
Official notice: https://www.grants.gov/search-results-detail/356017

> National Institutes of Health offered grants to small businesses. Applications closed on January 10, 2025.

| Field | Value |
|---|---|
| Opportunity number | RFA-CA-24-028 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | January 10, 2025 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.393, 93.394, 93.395, 93.396 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. See full Notice of Funding Opportunity Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to enable the provision of support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical trials; Management of issues of international importance in HIV associated-malignancies; and Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource (ACSR) for ongoing or future investigations. The AMC must consist of the following functional units: a Coordination Center; Clinical Trial Sites; Network Laboratories; and a Statistical Center. The AMC team must have scientific disease-oriented Working Groups to study Kaposi Sarcoma, Hematologic Malignancies , Human papilloma virus-associated cancers, and Solid Tumors in people with HIV. The Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions. All clinical trials to be conducted by the AMC must be available to subjects of all racial/ethnic groups.

## Questions people ask

### Is RFA-CA-24-028 still open?

No. It closed on January 10, 2025.

### Who can apply for Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required)?

Closed January 10, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-CA-24-028?

NIH RePORTER lists 1 project funded under RFA-CA-24-028 in fiscal 2025 to 2026, at 1 institution.

### Who has won Cancer Cause and Prevention Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.